Sedana Medical receives US patent for Sedaconda ACD-S
Sedana Medical AB (publ) announces that the US Patent and Trademark Office (USPTO) has granted Sedana Medical a patent for the medical device Sedaconda ACD-S (US Patent No. 11,707,593 B2). The patent will run until 2037.Sedaconda ACD-S is the main device in Sedana Medical’s therapy for inhaled sedation of mechanically ventilated patients in intensive care units. With an estimated market potential of 10-12 billion SEK, the United States constitutes the largest potential commercial opportunity for Sedana Medical. The company is currently conducting the INSPiRE-ICU Phase III clinical program